• BioSapien extends its pre-Series A round to over USD 8M, with new backing from MENA-based VC firm Globivest.
• The startup is developing MediChip™, a 3D-printed localized cancer treatment platform aligned with UAE’s health innovation goals.
• Globivest, a women-led impact VC, joins previous investors including Global Ventures, Golden Gate Ventures, and Dara Holdings.
  

BioSapien

What happened? UAE-based biotech startup, BioSapien, announced an extension to its pre-Series A funding round. This extension is backed by new investor Globivest. 

Dr. Laura-Joy Boulos, Partner at Globivest, said “At Globivest, we back companies that don’t just promise innovation – they deliver transformative, science-backed solutions with the power to shift paradigms. BioSapien’s MediChip™ platform is a breakthrough in localized cancer treatment – scalable, precise, and deeply aligned with our One Health mission. “

This extension brings its total pre-Series A funding to over USD 8 million with investors including Global Ventures, Golden Gate Ventures, and Dara Holdings.

This comes after the startup raised USD 5.5 million in December 2024 led by Global Ventures and Dara Holdings. Later on, in January 2025, it extended its pre-series A funding to USD 7 million also backed by the same investors.

What is the MediChip™? It is a localized cancer treatment platform that aims to enable sustained, targeted release of chemotherapeutics. The goal is to deliver the treatment directly at the tumor site to minimize systemic toxicity.

Biotech

Who are they? Biosapien is a clinical stage biotechnology company working on developing the future of  localized drug delivery through its proprietary biodegradable 3D-printed delivery platform. Furthermore, it is headquartered between the US and the UAE in alignment with the country’s vision to advance health innovation.

Globivest is a women-led, gender lens impact venture capital fund based in the MENA region. Moreover, it combines financial returns with science-backed impact. Thus, it aims to invest in tech-driven, early-stage startups at the intersection of health, social, and environmental innovation.